


PRV

PATENT- OCH REGISTRERINGSVERKET
 Patentavdelningen



**Intyg
 Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) *Sökande* *AstraZeneca AB, Södertälje SE*
Applicant (s)

(21) *Patentansökningsnummer* *0202465-1*
Patent application number

(86) *Ingivningsdatum* *2002-08-14*
Date of filing

Stockholm, 2003-08-19

För Patent- och registreringsverket
For the Patent- and Registration Office

Sonia André
 Sonia André

Avgift
Fee

PRIORITY DOCUMENT
 SUBMITTED OR TRANSMITTED IN
 COMPLIANCE WITH
 RULE 17.1(a) OR (b)

NEW COMPOUNDS**Technical Field**


This invention relates to novel bicyclic amides or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their
5 use in therapy. The invention also relates to compounds active as nicotinic acetylcholine receptors (nAChRs) agonists.

Background of the Invention

The use of compounds which bind nicotinic acetylcholine receptors in the treatment of a range of disorders involving reduced cholinergic function such as Alzheimer's disease,
10 cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease has been discussed in McDonald et al. (1995) "Nicotinic Acetylcholine Receptors: Molecular Biology, Chemistry and Pharmacology", Chapter 5 in Annual Reports in Medicinal Chemistry, vol. 30, pp. 41-50, Academic Press Inc., San Diego, CA; and in Williams et al. (1994) "Neuronal Nicotinic
15 Acetylcholine Receptors," Drug News & Perspectives, vol. 7, pp. 205-223.



Disclosure of the Invention

The invention comprises compounds of formula I



wherein:

- 20 a, b and c are each 1 or 2;
D is oxygen or sulfur, and
R is selected from moieties of formulae II, III or IV:



25 wherein

R¹, and R² are independently selected from hydrogen, CN, CF₃, halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl or CO₂R³;

Ar is phenyl, or

Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

- 5 Ar is an 8-, 9- or 10-membered fused aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

- 10 Ar is an 8-, 9- or 10-membered aromatic carbocyclic ring, said phenyl, heterocyclic rings or carbocyclic having 0, 1 or more substituents independently selected from hydrogen, CN, NO₂, CF₃, halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, aryl, heteroaryl, OR³, CO₂R³ or NR³R⁴;

where:

R³ and R⁴ are independently at each occurrence selected from hydrogen, C₁₋₄alkyl, aryl, heteroaryl, C(O)R⁵, C(O)NHR⁵, CO₂R⁵, SO₂R⁶, or

- 15 R³, R⁴ and N in combination in the substituent -NR³R⁴ is (CH₂)_jQ(CH₂)_k where Q is O, S, NR⁵, or a bond; j is 2, 3 or 4 and k is 0, 1 or 2;

wherein

R⁵ at each occurrence is independently selected from hydrogen, C₁₋₄alkyl, aryl, or heteroaryl, and

- 20 R⁶ at each occurrence is independently selected from C₁₋₄alkyl, aryl, or heteroaryl.

Another embodiment of the invention comprises compounds wherein D is oxygen.

Yet another embodiment of the invention comprises compounds wherein a is 1, b is 2 and c is 1.

- 25 Still another embodiment of the invention comprises compounds wherein Ar is phenyl, or Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur.

Another embodiment of the invention comprises compounds wherein Ar is a phenyl, furanyl or thiophenyl.

- 30 Particular compounds of the invention are those wherein a is 1, b is 2, c is 1, D is oxygen, R¹ and R² are hydrogen and Ar is phenyl, or Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur

where not more than one of said heteroatoms is oxygen or sulfur, or Ar is an 8-, 9- or 10-membered fused aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or Ar is an 8-, 9- or 10-membered aromatic carbocyclic ring.

5 Particular compounds of the invention are also those wherein Ar is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, benzofuran-2-yl; benzofuran-3-yl, benzo[b]thiophen-2-yl or benzo[b]thiophen-3-yl.

Particular compounds of the invention are also those wherein Ar is substituted with one or more substituents independently chosen from CN, NO₂, CF₃, halogen, C₁₋₄alkyl,
10 C₂₋₄alkenyl, C₂₋₄alkynyl, aryl, heteroaryl, OR³, CO₂R³ and NR³R⁴.

Most particular compounds of the invention include:

(1,4-diazabicyclo[3.2.2]non-4-yl)(phenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3-fluorophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-fluorophenyl)methanone;
15 (3-chlorophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(4-chlorophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3,4-dichlorophenyl)methanone;
(3-bromophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(4-bromophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
20 (1,4-diazabicyclo[3.2.2]non-4-yl)(3-iodophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-iodophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-trifluoromethylphenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-methoxyphenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-trifluoromethoxyphenyl)methanone;
25 (1,4-diazabicyclo[3.2.2]non-4-yl)(furan-2-yl)methanone;
(5-chlorofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-bromofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-iodofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(thiophen-2-yl)methanone;
30 (5-chlorothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-bromothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-iodothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;

- (1,4-diazabicyclo[3.2.2]non-4-yl)(naphthalen-2-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(benzofuan-2-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(benzo[b]thiophen-2-yl)methanone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-phenylpropenone;
5 1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-phenylpropynone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(furan-2-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(furan-3-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(thiophen-2-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(thiophen-3-yl)propenone, and
10 (1,4-diazabicyclo[3.2.2]non-4-yl)(fuan-2-yl)methanone.

Each embodiment and particular form of the invention encompass all diastereoisomers, enantiomers and pharmaceutically-acceptable derivatives and salts of compounds thereof.

- Pharmaceutically-acceptable derivatives include solvates and salts. For example, the
15 compounds of formula I can form acid addition salts with acids, such as the conventional pharmaceutically-acceptable acids, for example, maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulfonic acids.

- Compounds of the invention are useful in the treatment or prophylaxis of human
20 diseases or conditions in which activation of the $\alpha 7$ nicotinic receptor is beneficial as well as in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders. Examples of such conditions, diseases or disorders are Alzheimers disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, Anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntington's
25 disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotinic addiction including that resulting from exposure to products containing nicotine, pain, for ulcerative colitis and irritable bowel disease.

- As used herein, unless otherwise indicated, "C₁₋₄alkyl" includes but is not limited to
30 methyl, ethyl, n-propyl, n-butyl, i-propyl, i-butyl, t-butyl, s-butyl moieties, whether alone or part of another group, C₁₋₄alkyl groups may be straight-chained or branched, and C₃₋₄alkyl

groups include the cyclic alkyl moieties cyclopropyl and cyclobutyl. Alkyl groups referred to herein may have 1, 2 or 3 halogen substituents.

As used herein, unless otherwise indicated, "C₂₋₄alkenyl" includes but is not limited to 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl and 3-butenyl.

5 As used herein, unless otherwise indicated, "C₂₋₄alkynyl" includes but is not limited to ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl and 3-butylnyl.


As used herein, unless otherwise indicated, aryl refers to a phenyl ring which may have 1, 2 or 3 substituents selected from CN, NO₂, CF₃, halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, OC₁₋₄alkyl, NH₂ and CO₂C₁₋₄alkyl.

10 As used herein, unless otherwise indicated, heteroaryl refers to a 5- or 6-membered aromatic or heteroaromatic ring having 0, 1, 2 or 3 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom, provided that the ring contains at least one nitrogen, oxygen, or sulfur atom. Heteroaryl moieties may have one or more substituents selected from CN, NO₂, CF₃, halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, NH₂, CO₂H, OC₁₋₄alkyl and CO₂C₁₋₄alkyl.

15 As used herein, unless otherwise indicated, halogen refers to fluorine, chlorine, bromine, or iodine.

Methods of Preparation

In the reaction schemes and text that follow, D and R, unless otherwise indicated, are as defined above for formula I. The compounds of formula I may be prepared according to the
20 methods outlined in Scheme 1.



Scheme 1

Compounds of formula I wherein D represents O may be prepared from compounds of formula III by reaction with a compound of formula II, wherein Y represents a suitable leaving group, using a suitable acylation procedure. Suitable leaving groups Y include: OH, halogen, Oalkyl, Oaryl, OCOalkyl, OCOaryl, azide. A suitable acylation procedure involves treatment of a compound of formula III with a compound of formula II at 0-120 °C in a suitable solvent. The presence of a base, or, when Y=OH, a coupling agent, may also be necessary for the reaction to occur. Suitable bases for the reaction include: 4-(*N,N*-dimethylamino)pyridine, pyridine, triethylamine, *N,N*-diisopropylethylamine. The preferred base is *N,N*-diisopropylethylamine. Suitable coupling agents when Y=OH include: carbodiimides, for example 1,3-dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride; phosphonium reagents, for example benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; and uronium reagents, for example *O*-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium tetrafluoroborate. The preferred coupling agent is *O*-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium tetrafluoroborate. Suitable solvents for the reaction include *N,N*-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, or chloroform. The preferred solvent is *N,N*-dimethylformamide. The reaction is preferably performed at a temperature of 0-50 °C, and most preferably at a temperature of 20-30 °C.

Compounds of formula I in which D represents S may be prepared from compounds of formula I in which D represents O by reaction with a suitable sulfide in a suitable solvent.

The preferred sulfides are phosphorus sulfides, in particular 4-methoxyphenylthionophosphine sulfide dimer ("Lawesson's Reagent"), and diphosphorus pentasulfide. Suitable solvents for the reaction include aryl hydrocarbon solvents, for example toluene or xylene. The reaction is performed at a temperature of 0-200 °C, and preferably at a temperature of 50-180 °C.

It will be appreciated by one skilled in the art that certain optional aromatic substituents in the compounds of the invention may be introduced by employing aromatic substitution reactions, or functional group transformations to modify an existing substituent, or a combination thereof. Such reactions may be effected either prior to or immediately following the processes mentioned above, and are included as part of the process aspect of the invention. The reagents and reaction conditions for such procedures are known in the art.

Specific examples of procedures which may be employed include, but are not limited to, electrophilic functionalisation of an aromatic ring, for example via nitration, halogenation, or acylation; transformation of a nitro group to an amino group, for example via reduction, such as by catalytic hydrogenation; acylation, alkylation or sulfonylation of an amino or hydroxyl group; replacement of an amino group by another functional group via conversion to an intermediate diazonium salt followed by nucleophilic or free radical substitution of the diazonium salt; or replacement of a halogen by another functional group for example via nucleophilic or catalysed substitution reactions.

Where necessary, hydroxy, amino, or other reactive groups may be protected using a protecting group as described in the standard text "Protecting groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

The above described reactions, unless otherwise noted, are usually conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere). Unless otherwise stated, the above described reactions are conducted under an inert atmosphere, preferably under a nitrogen atmosphere.

The compounds of the invention and intermediates may be isolated from their reaction mixtures by standard techniques.

Acid addition salts of the compounds of formula I which may be mentioned include salts of mineral acids, for example the hydrochloride and hydrobromide salts; and salts formed with organic acids such as formate, acetate, maleate, benzoate, tartrate, and fumarate salts.

Acid addition salts of compounds of formula I may be formed by reacting the free base or a salt, enantiomer or protected derivative thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, e.g., water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuum or by freeze drying. The reaction may be a metathetical process or it may be carried out on an ion exchange resin.

The compounds of formula I exist in tautomeric or enantiomeric forms, all of which are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, e.g. fractional crystallization, or chiral HPLC. Alternatively the individual enantiomers may be

made by reaction of the appropriate optically active starting materials under reaction conditions which will not cause racemization

Pharmaceutical compositions

A further aspect of the invention relates to a pharmaceutical composition for treating or preventing a condition or disorder as exemplified below arising from dysfunction of nicotinic acetylcholine receptor neurotransmission in a mammal, preferably a human, comprising an amount of a compound of formula I, an enantiomer thereof or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and an inert pharmaceutically acceptable carrier.

For the above-mentioned uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.1 mg to about 20 mg per kg of animal body weight, preferably given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose is in the range of from 5 mg to 1,400 mg, more preferably from 10 mg to 100 mg, and unit dosage forms suitable for oral administration comprise from 2 mg to 1,400 mg of the compound admixed with a solid or liquid pharmaceutical carrier or diluent.

The compounds of formula I, enantiomers thereof, and pharmaceutically-acceptable salts thereof, may be used on their own or in the form of appropriate medicinal preparations for enteral or parenteral administration. According to a further aspect of the invention, there is provided a pharmaceutical composition including preferably less than 80% and more preferably less than 50% by weight of a compound of the invention in admixture with an inert pharmaceutically acceptable diluent or carrier.

25 **Examples of diluents and carriers are:**

- for tablets and dragees: lactose, starch, talc, stearic acid;
- capsules: tartaric acid or lactose;
- for injectable solutions: water, alcohols, glycerin, vegetable oils;
- for suppositories: natural or hardened oils or waxes.

30 There is also provided a process for the preparation of such a pharmaceutical composition, which comprises mixing the ingredients.

One aspect of the invention is the use of a compound according to the invention, an enantiomer thereof or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of one of the below mentioned diseases or conditions; and a method of treatment or prophylaxis of one of the above mentioned diseases or conditions, which comprises administering a therapeutically effective amount of a compound according to the invention, or an enantiomer thereof or a pharmaceutically acceptable salt thereof, to a patient.

Compounds to be used according to the invention are agonists of nicotinic acetylcholine receptors. While not being limited by theory, it is believed that agonists of the α_7 nAChR (nicotinic acetylcholine receptor) subtype should be useful in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, and have advantages over compounds which are or are also agonists of the α_4 nAChR subtype. Therefore, compounds which are selective for the α_7 nAChR subtype are preferred. The use of compounds of the invention are indicated as pharmaceuticals, in particular in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders. Examples of psychotic disorders include schizophrenia, mania and manic depression, and anxiety. Examples of intellectual impairment disorders include Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, and Attention Deficit Hyperactivity Disorder. The compounds of the invention may also be useful as analgesics in the treatment of pain (including chronic pain) and in the treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome, and neurodegenerative disorders in which there is loss of cholinergic synapses. The compounds may further be indicated for the treatment or prophylaxis of jetlag, for use in inducing the cessation of smoking, and for the treatment or prophylaxis of nicotine addiction (including that resulting from exposure to products containing nicotine).

It is also believed that compounds according to the invention are useful in the treatment and prophylaxis of ulcerative colitis.

Pharmacology

The pharmacological activity of the compounds of the invention may be measured in the tests set out below:

Test A - Assay for affinity at α_7 nAChR subtype

¹²⁵I- α -Bungarotoxin (BTX) binding to rat hippocampal membranes.

Rat hippocampi were homogenized in 20 volumes of cold homogenization buffer (HB: concentrations of constituents (mM): tris(hydroxymethyl)aminomethane 50; MgCl_2 1; NaCl 120; KCl 5; pH 7.4). The homogenate was centrifuged for 5 minutes at 1000 xg, the supernatant was saved and the pellet re-extracted. The pooled supernatants were centrifuged
5 for 20 minutes at 12000 xg, washed, and resuspended in HB. Membranes (30–80 μg) were incubated with 5 nM [^{125}I]- α -BTX, 1 mg/mL BSA (bovine serum albumin), test drug, and either 2 mM CaCl_2 or 0.5 mM EGTA [ethylene glycol-bis(β -aminoethylether)] for 2 hours at 21 °C, and then filtered and washed 4 times over Whatman glass fibre filters (thickness C)
10 using a Brandel cell harvester. Pretreating the filters for 3 hours with 1% (BSA/0.01% PEI (polyethyleneimine) in water was critical for low filter blanks (0.07% of total counts per minute). Nonspecific binding was described by 100 μM (–)-nicotine, and specific binding was typically 75%.

Test B - Assay for affinity to the α_4 nAChR subtype

[^3H]-(-)-nicotine binding.

15 Using a procedure modified from Martino-Barrows and Kellar (Mol Pharm (1987) 31:169-174), rat brain (cortex and hippocampus) was homogenized as in the [^{125}I]- α -BTX binding assay, centrifuged for 20 minutes at 12,000 xg, washed twice, and then resuspended in HB containing 100 μM diisopropyl fluorophosphate. After 20 minutes at 4 °C, membranes (approximately 0.5 mg) were incubated with 3 nM [^3H]-(-)-nicotine, test drug, 1 μM
20 atropine, and either 2 mM CaCl_2 or 0.5 mM EGTA for 1 hour at 4 °C, and then filtered over Whatman glass fibre filters (thickness C) (pretreated for 1 hour with 0.5% PEI) using a Brandel cell harvester. Nonspecific binding was described by 100 μM carbachol, and specific binding was typically 84%.

Binding data analysis for Tests A and B

25 IC_{50} values and pseudo Hill coefficients (nH) were calculated using the non-linear curve fitting program ALLFIT (DeLean A, Munson P J and Rodbard D (1977) Am. J. Physiol., 235:E97-E102). Saturation curves were fitted to a one site model, using the non-linear regression program ENZFITTER (Leatherbarrow, R.J. (1987)), yielding KD values of 1.67 and 1.70 nM for the ^{125}I - α -BTX and [^3H]-(-)-nicotine ligands respectively. K_i values
30 were estimated using the general Cheng-Prusoff equation:

$$K_i = [IC_{50}] / ((2 + ([ligand] / [K_D])^n)^{1/n} - 1)$$

where a value of $n=1$ was used whenever $^nH < 1.5$ and a value of $n=2$ was used when $^nH \geq 1.5$.


Samples were assayed in triplicate and were typically $\pm 5\%$. K_i values were determined using

- 5 6 or more drug concentrations. The compounds of the invention are compounds with binding affinities (K_i) of less than 10 nM in either Test A or Test B, indicating that they are expected to have useful therapeutic activity.

- 10 The compounds of the invention have the advantage that they may be less toxic, be more efficacious, be longer acting, have a broader range of activity, be more potent, produce fewer side effects, are more easily absorbed or have other useful pharmacological properties.

CLAIMS

1. A compound of formula I:




5 wherein:

a, b and c are each 1 or 2;

D is oxygen or sulfur, and

R is selected from moieties of formulae II, III or IV:



10

wherein

R¹, and R² are independently selected from hydrogen, CN, CF₃, halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl or CO₂R³;

Ar is phenyl, or

15 Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar is an 8-, 9- or 10-membered fused aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said

20 heteroatoms is oxygen or sulfur, or

Ar is an 8-, 9- or 10-membered aromatic carbocyclic ring, said phenyl, heterocyclic rings or carbocyclic having 0, 1 or more substituents independently selected from hydrogen, CN, NO₂, CF₃, halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, aryl, heteroaryl, OR³, CO₂R³ or NR³R⁴;

25 where:

R³ and R⁴ are independently at each occurrence selected from hydrogen, C₁₋₄alkyl, aryl, heteroaryl, C(O)R⁵, C(O)NHR⁵, CO₂R⁵, SO₂R⁶, or

-13-

R^3 , R^4 and N in combination in the substituent $-NR^3R^4$ is $(CH_2)_jQ(CH_2)_k$ where Q is O, S, NR^5 , or a bond; j is 2, 3 or 4 and k is 0, 1 or 2;

wherein

5 R^5 at each occurrence is independently selected from hydrogen, C_{1-4} alkyl, aryl, or heteroaryl, and

R^6 at each occurrence is independently selected from C_{1-4} alkyl, aryl, or heteroaryl; or an enantiomer or pharmaceutically-acceptable salt thereof.

10 2. A compound according to Claim 1, wherein D is oxygen.

3. A compound according to Claim 1, wherein a is 1, b is 2 and c is 1, or an enantiomer or pharmaceutically-acceptable salt thereof.

15 4. A compound of Claim 1, wherein

Ar is phenyl, or

Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur;

or an enantiomer or pharmaceutically-acceptable salt thereof.

20

5. A compound according to Claim 4, wherein Ar is a phenyl, furanyl or thiophenyl; or an enantiomer or pharmaceutically-acceptable salt thereof.

25 6. A compound according to Claim 1, wherein:

a is 1;

b is 2;

c is 1;

D is oxygen;

R^1 and R^2 are hydrogen;

30 Ar is phenyl, or

Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar is an 8-, 9- or 10-membered fused aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar is an 8-, 9- or 10-membered aromatic carbocyclic ring;
or an enantiomer or pharmaceutically-acceptable salt thereof.

7. A compound according to Claim 1, wherein:

Ar is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, benzofuran-2-yl; benzofuran-3-yl, benzo[b]thiophen-2-yl or benzo[b]thiophen-3-yl;
or an enantiomer or pharmaceutically-acceptable salt thereof.

8. A compound according to Claim 1, wherein:

Ar is substituted with one or more substituents independently chosen from CN, NO₂, CF₃, halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, aryl, heteroaryl, OR³, CO₂R³ and NR³R⁴;
or an enantiomer or pharmaceutically-acceptable salt thereof.

9. A compound according to Claim 1 selected from:

(1,4-diazabicyclo[3.2.2]non-4-yl)(phenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3-fluorophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-fluorophenyl)methanone;
(3-chlorophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(4-chlorophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3,4-dichlorophenyl)methanone;
(3-bromophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(4-bromophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3-iodophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-iodophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-trifluoromethylphenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-methoxyphenyl)methanone;

- (1,4-diazabicyclo[3.2.2]non-4-yl)(4-trifluoromethoxyphenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(furan-2-yl)methanone;
(5-chlorofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-bromofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
5 (5-iodofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(thiophen-2-yl)methanone;
(5-chlorothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-bromothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-iodothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
10 (1,4-diazabicyclo[3.2.2]non-4-yl)(naphthalen-2-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(benzofuran-2-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(benzo[b]thiophen-2-yl)methanone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-phenylpropenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-phenylpropynone;
15 1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(furan-2-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(furan-3-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(thiophen-2-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(thiophen-3-yl)propenone, and
(1,4-diazabicyclo[3.2.2]non-4-yl)(furan-2-yl)methanone,
20 or an enantiomer or pharmaceutically-acceptable salt thereof.

10. A compound according to any one of Claims 1 to 10, for use in therapy.
11. A compound according to any one of Claims 1 to 10, for use as a medicament.
- 25 12. Use of a compound as defined in any one of claims 1 to 10, in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders, human diseases or conditions in which activation of the $\alpha 7$ nicotinic receptor is beneficial, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia,
30 mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of


smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, ulcerative colitis or irritable bowel syndrome.

13. A method of treatment or prophylaxis of psychotic disorders, intellectual impairment
5 disorders, human diseases or conditions in which activation of the $\alpha 7$ nicotinic receptor is beneficial, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of
10 smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, or ulcerative colitis which method comprises administering a therapeutically effective amount of a compound as defined in any one of Claims 1 to 10.

14. A pharmaceutical composition comprising a compound of formula I, as defined in
15 any one of claims 1 to 10, together with at least one pharmaceutically-acceptable excipient or diluent.

ABSTRACT

Nicotinic acetylcholine receptor agonists of formula I



- 5 wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.